Evidence map›Paper›PMID 32387456›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2020

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).

M Montopoli, S Zumerle, R Vettor, M Rugge, M Zorzi, C V Catapano, G M Carbone, A Cavalli, F Pagano, E Ragazzi and 2 more

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 317 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
317citing papers in PubMed, 11 pooled it
42.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04446429 nacompletednot on this map

Anti-Androgen Treatment for COVID-19

TypeinterventionalSponsorApplied Biology, Inc.Ran2020 to 2021Enrolled268ConditionsCOVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate CancerArmsProxalutamide, Standard of Care
NCT04728802 phase3completednot on this mapstarted 2021, after this paper: background citation

Proxalutamide Treatment for Hospitalized COVID-19 Patients

TypeinterventionalSponsorApplied Biology, Inc.Ran2021 to 2021Enrolled645ConditionsCovid19, SARS (Severe Acute Respiratory Syndrome)ArmsProxalutamide, Placebo
3 · Its place in the literature

Who cites it

317 citing papers in PubMed, 11 syntheses or guidelines pooled it, 544 citations in OpenAlex.

  1. Pooled it
  2. [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Review
  15. Sex Differences in Lung Immunity.Immunological reviews · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

257 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

M MontopoliDepartment of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy; VIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy.
S ZumerleVIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy; Department of Medicine, Università degli Studi di Padova, Padova, Italy.
R VettorDepartment of Medicine, Università degli Studi di Padova, Padova, Italy.
M RuggeDepartment of Medicine, Università degli Studi di Padova, Padova, Italy; Veneto Tumour Registry - Azienda Zero, Padova, Italy.
M ZorziVeneto Tumour Registry - Azienda Zero, Padova, Italy.
C V CatapanoInstitute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland.
G M CarboneInstitute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland.
A CavalliInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
F PaganoVIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy.
E RagazziDepartment of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy.
T Prayer-GalettiDepartment of Oncological and Gastroenterological Sciences - Urology Unit, Azienda Ospedaliera di Padova, Padova, Italy.
A AlimontiVIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy; Department of Medicine, Università degli Studi di Padova, Padova, Italy; Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland; Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland. Electronic address: andrea.alimonti@ior.iosi.ch.
University of Padua · ITInstitute of Oncology Research · CHAzienda Ospedale - Università Padova · ITFondazione Progetto Ematologia · ITUniversità della Svizzera italiana · CHVeneto Institute of Molecular Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of the viral spike (S) proteins to angiotensin-converting enzyme 2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is up-regulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. MATERIALS AND

methodsWe extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the coronavirus disease 2019 (COVID-19) pandemic. The parameters used for each COVID-19-positive patient were sex, hospitalization, admission to intensive care unit, death, tumor diagnosis, prostate cancer diagnosis, and ADT.

resultsThere were evaluable 9280 SARS-CoV-2-positive patients in Veneto on 1 April 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2-positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared with patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT with patients with any other type of cancer (OR 4.86; 95% CI 1.88-12.56).

conclusionOur data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.

Indexed as

BetacoronavirusPopulation SurveillanceAgedAged, 80 and overAndrogen AntagonistsCoronavirus InfectionsCOVID-19HumansItalyMaleMiddle AgedPandemicsPneumonia, ViralProstatic NeoplasmsRisk FactorsSARS-CoV-2Androgen Antagonistsandrogen-deprivation therapyCOVID-19prostate cancer

Identifiers

PMID32387456
PMCPMC7202813
OpenAlexW3023316367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.